Published in Pharmacogenomics on April 01, 2013
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics (2013) 0.77
Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity. BMC Genomics (2015) 0.76
Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to Glucose. PLoS One (2016) 0.75
Gene expression and proliferation biomarkers for antidepressant treatment resistance. Transl Psychiatry (2017) 0.75
Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines. Genome Med (2015) 0.75
Genetic screening reveals a link between Wnt signaling and antitubulin drugs. Pharmacogenomics J (2015) 0.75
Population genomics of human gene expression. Nat Genet (2007) 24.49
Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature (2010) 16.86
DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol (2011) 6.48
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med (2011) 3.80
Genetic analysis of radiation-induced changes in human gene expression. Nature (2009) 2.30
Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods (2010) 2.20
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
The effects of EBV transformation on gene expression levels and methylation profiles. Hum Mol Genet (2011) 1.74
Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation (2008) 1.64
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Population differences in microRNA expression and biological implications. RNA Biol (2011) 1.33
Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A (2012) 1.26
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics (2012) 1.23
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res (2011) 1.22
Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol (2010) 1.19
Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther (2012) 1.15
Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia (2011) 0.92
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics (2013) 0.90
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A (2010) 2.43
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet (2008) 1.96
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res (2007) 1.73
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics. Bioinform Biol Insights (2008) 1.73
Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther (2008) 1.67
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res (2008) 1.57
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res (2009) 1.48
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun (2013) 1.43
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation (2008) 1.41
Population differences in microRNA expression and biological implications. RNA Biol (2011) 1.33
Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics (2013) 1.31
Exprtarget: an integrative approach to predicting human microRNA targets. PLoS One (2010) 1.31
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol (2007) 1.31
Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet (2008) 1.26
Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A (2012) 1.26
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Variants affecting exon skipping contribute to complex traits. PLoS Genet (2012) 1.24
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev (2006) 1.23
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther (2005) 1.23
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res (2011) 1.22
Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects. Curr Bioinform (2008) 1.19
Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med (2008) 1.18
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics (2005) 1.13
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics (2010) 1.12
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther (2009) 1.11
Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet (2012) 1.08
Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol (2009) 1.07
Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics (2008) 1.06
Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther (2008) 1.06
On the challenges of the HapMap resource. Bioinformation (2008) 1.06
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther (2002) 1.04
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics (2009) 1.04
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res (2012) 1.03
Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet (2010) 1.00
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs (2008) 0.99
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics (2007) 0.99
Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biol (2009) 0.99
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One (2011) 0.99
Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics (2010) 0.97
Genetics and variable drug response. JAMA (2011) 0.96
Population-specific GSTM1 copy number variation. Hum Mol Genet (2008) 0.96
Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol (2005) 0.95
Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res (2007) 0.95
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics (2012) 0.94
Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res (2002) 0.94
Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des (2009) 0.93
Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol (2011) 0.93
Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics (2009) 0.92
Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One (2010) 0.92
Poly-omic prediction of complex traits: OmicKriging. Genet Epidemiol (2014) 0.91
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis (2006) 0.91
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol (2006) 0.91
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther (2004) 0.90
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol (2007) 0.89
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther (2004) 0.89
Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics (2009) 0.89
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer (2012) 0.89
Temozolomide: realizing the promise and potential. Curr Opin Oncol (2003) 0.88
A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics (2009) 0.88
Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst) (2007) 0.88
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res (2008) 0.87
Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics (2008) 0.87
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res (2011) 0.86
Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics (2003) 0.86
Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther (2003) 0.86
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol (2004) 0.85
Allelic loss at the GPx-1 locus in cancer of the head and neck. Biol Trace Elem Res (2004) 0.85
The emerging role of microRNAs in drug responses. Curr Opin Mol Ther (2010) 0.85
Integrative genomics: quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet (2013) 0.85